Generated LUMRYZ™ net product revenue of $77.5 million, a 55% increase compared to third quarter 2024 –– Approximately 3,400 patients on LUMRYZ ...

A seven-year-old girl lies in critical condition, her body scarred by burns inflicted deliberately with a heated spoon .

November is National Diabetes Awareness Month, a time to talk about the disease that affects more than 38 million people ...

In the run up to the B&T Awards (28 November at Sydney’s Hordern Pavilion), we’re taking a look at the excellent work of this year’s finalists. This time out, we’re taking a look at the finalists in ...

Gaza's residents face a mental health crisis following a brutal Israeli military campaign. Over 68,000 fatalities, ...

Other risk factors for kidney disease include chronic infections, autoimmune disorders, and certain genetic variants. The new ...

One monoclonal antibody, rituximab, can work wonders for the treatment of children with frequently relapsing nephrotic ...

Researchers from The University of Osaka have found that rituximab, a monoclonal antibody approved for the treatment of ...

The results of two large-scale studies demonstrate that sodium-glucose co-transporter 2 (SGLT2) inhibitors significantly ...

More generally, be mindful of what you eat and drink before bed. A good rule of thumb is to avoid water and other fluids two ...

One monoclonal antibody, rituximab, can work wonders for the treatment of children with frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome. However, what about patients ...

Type 1 diabetes with CKD is understudied with no advancement of therapy options since the 1990s. The FINE-ONE phase 3 trial addresses a high, unmet need for treatments.